Get started
Work

62P First-line (1L) camrelizumab plus chemotherapy (chemo) for advanced squamous non-small cell lung cancer (sqNSCLC): 4-yr update from the phase III CameL-sq trial

Year: 2024
Type: article
Abstract: In the phase III CameL-sq trial, camrelizumab + chemo as 1L treatment significantly extended PFS vs placebo + chemo in patients (pts) with advanced sqNSCLC. Here we report the outcomes 4 yrs after enrollment of the last pt.
Source: ESMO Open
DOI: 10.1016/j.esmoop.2024.102641
Authors: C. Zhou, S. Ren, J. Chen, X. Xu, Y. Cheng, G. Chen, Y. Pan, Y. Fang, Q-M. Wang, Y. Huang, W. Yao, R. Wang, X. Li, W. Zhang, Y. Zhang, S. Hu, R-H. Guo, D. Wang, Z. Wang, X. Lu
Institutions: Tongji University, Shanghai Pulmonary Hospital, Hunan Cancer Hospital, Northern Jiangsu People's Hospital, Jilin Province Tumor Hospital, Harbin Medical University, Anhui Provincial Hospital, Sir Run Run Shaw Hospital, Zhejiang University, Zhengzhou University, Henan Cancer Hospital, Kunming Medical University, University of Electronic Science and Technology of China, Sichuan Cancer Hospital, First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital of Nanchang University, Hubei Cancer Hospital, Jiangsu Province Hospital, Chongqing Cancer Hospital, Jiangsu Hengrui Medicine (China)
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,730
OpenAlex ID: W4393166341
FWCI: 2.327
Cites:
Cited by: 9
Related to: 10